NAA80

Summary

NAA80 (N-alpha-acetyltransferase 80, NatH catalytic subunit, HGNC:30252) is a protein-coding gene on chromosome 3p21.31, encoding N-alpha-acetyltransferase 80 (Q93015). N-alpha-acetyltransferase that specifically mediates the acetylation of the acidic amino terminus of processed forms of beta- and gamma-actin (ACTB and ACTG, respectively).

This gene encodes a member of the N-acetyltransferase family. N-acetyltransferases modify proteins by transferring acetyl groups from acetyl CoA to the N-termini of protein substrates. The encoded protein is a cytoplasmic N-acetyltransferase with a substrate specificity for proteins with an N-terminal methionine. This gene is located in the tumor suppressor gene region on chromosome 3p21.3 and the encoded protein may play a role in cancer. Alternatively spliced transcript variants encoding multiple isoforms have been observed. This gene overlaps and is on the same strand as hyaluronoglucosaminidase 3, and some transcripts of each gene share a portion of the first exon.

Source: NCBI Gene 24142 — RefSeq curated summary.

At a glance

• Gene–disease (curated): auroneurodental syndrome (Limited, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 2 total
• Phenotypes (HPO): 29
• MANE Select transcript: NM_001200016

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30252
Approved symbol	NAA80
Name	N-alpha-acetyltransferase 80, NatH catalytic subunit
Location	3p21.31
Locus type	gene with protein product
Status	Approved
Aliases	FUS2
Ensembl gene	ENSG00000243477
Ensembl biotype	protein_coding
OMIM	607073
Entrez	24142

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 9 protein_coding

ENST00000354862, ENST00000417393, ENST00000442620, ENST00000443094, ENST00000443842, ENST00000450489, ENST00000452674, ENST00000885805, ENST00000919720

RefSeq mRNA: 3 — MANE Select: NM_001200016 NM_001200016, NM_001200018, NM_012191

CCDS: CCDS43095, CCDS56258

Canonical transcript exons

ENST00000443094 — 2 exons

Exon	Start	End
ENSE00001400484	50299213	50299405
ENSE00001710718	50296402	50297672

Expression profiles

Bgee: expression breadth ubiquitous, 172 present calls, max score 94.04.

FANTOM5 (CAGE): breadth broad, TPM avg 0.6918 / max 25.0367, expressed in 408 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
42308	9.0812	1779
42309	4.0640	1638
42306	3.1356	1095
42307	0.6228	358
42305	0.0690	18

Top tissues by expression

285 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	94.04	gold quality
right testis	UBERON:0004534	93.76	gold quality
testis	UBERON:0000473	91.00	gold quality
apex of heart	UBERON:0002098	88.51	gold quality
right hemisphere of cerebellum	UBERON:0014890	88.33	gold quality
granulocyte	CL:0000094	87.61	gold quality
right frontal lobe	UBERON:0002810	87.44	gold quality
cerebellar hemisphere	UBERON:0002245	86.92	gold quality
cerebellar cortex	UBERON:0002129	86.77	gold quality
skin of abdomen	UBERON:0001416	86.37	gold quality
body of stomach	UBERON:0001161	85.81	gold quality
right lung	UBERON:0002167	85.61	gold quality
prefrontal cortex	UBERON:0000451	85.58	gold quality
skin of leg	UBERON:0001511	85.39	gold quality
sperm	CL:0000019	85.34	silver quality
left ovary	UBERON:0002119	84.99	gold quality
hindlimb stylopod muscle	UBERON:0004252	84.77	gold quality
ectocervix	UBERON:0012249	84.72	gold quality
right ovary	UBERON:0002118	84.65	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.63	gold quality
tibial nerve	UBERON:0001323	84.36	gold quality
left uterine tube	UBERON:0001303	84.34	gold quality
gastrocnemius	UBERON:0001388	84.31	gold quality
cerebellum	UBERON:0002037	84.24	gold quality
body of uterus	UBERON:0009853	84.02	gold quality
male germ cell	CL:0000015	83.99	silver quality
metanephros cortex	UBERON:0010533	83.94	gold quality
descending thoracic aorta	UBERON:0002345	83.78	gold quality
mucosa of stomach	UBERON:0001199	83.75	gold quality
right coronary artery	UBERON:0001625	83.75	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-MTAB-6142	no	56.06
E-ANND-3	no	2.22

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

15 targeting NAA80, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-4649-3P	99.56	66.90	1783
HSA-MIR-1912-3P	99.32	67.40	936
HSA-MIR-7160-5P	99.11	67.17	2207
HSA-MIR-4656	98.79	66.22	1306
HSA-MIR-502-5P	98.77	66.51	906
HSA-MIR-3188	98.58	65.60	878
HSA-MIR-1199-5P	98.44	66.51	829
HSA-MIR-6751-3P	98.44	66.35	835
HSA-MIR-4691-3P	98.11	66.83	1204
HSA-MIR-6085	96.57	64.11	621
HSA-MIR-1915-5P	95.25	65.78	571
HSA-MIR-6813-5P	94.68	64.20	588
HSA-MIR-6775-5P	92.43	61.00	132

Literature-anchored findings (GeneRIF, showing 11)

• Characterization of the murine hyaluronidase gene region reveals complex organization and cotranscription of Hyal1 with downstream genes, Fus2 and Hyal3. (PMID:11929860)
• newly identified polymorphism leads to a non-conservative amino acid change (R222W) located between the acetyltransferase and the proline-rich domains; analysis suggests no likely association between nasopharyngeal cancer and the FUS2 gene polymorphism (PMID:15036368)
• NAT6/FUS-2 is the N-alpha acetyltransferase 80 (NAA80/NatH) acting post-translationally and specifically on processed animal actins. This NAA80 mediated actin N-terminal acetylation is crucial for actin polymerization and depolymerization, and regulates the actin cytoskeleton and cell motility. (PMID:29581253)
• the results demonstrate NAA80’s role as actin’s NAT and reveal a crucial role for actin Nt-acetylation in the control of cytoskeleton structure and dynamics. (PMID:29581253)
• NAA80/NatH is dedicated to the post-translational N-terminal acetylation of processed actins. The structure of NAA80 reveals features like a positively charged catalytic groove perfectly suited to bind the acidic actin N-terminus. A cellular factor restricting NAA80 to processed actins is NatB, which co-translationally acetylates all cellular Met-starting N-termini with acidic amino acids at the second position. (PMID:29581307)
• this study reveals the molecular and cellular basis of NAA80 Nt acetylation and provides a scaffold for development of inhibitors for the regulation of cytoskeletal properties. (PMID:29581307)
• findings reveal that NAT6 plays a critical role in the maturation of actins by carrying out the acetylation of their N-terminal acidic residue (PMID:30028079)
• N-terminal acetylation of actin by NAA80 is essential for structural integrity of the Golgi apparatus. (PMID:32209306)
• PFN2 and NAA80 cooperate to efficiently acetylate the N-terminus of actin. (PMID:32978259)
• The Final Maturation State of beta-actin Involves N-terminal Acetylation by NAA80, not N-terminal Arginylation by ATE1. (PMID:34896361)
• N-terminal acetyltransferase 6 facilitates enterovirus 71 replication by regulating PI4KB expression and replication organelle biogenesis. (PMID:38189249)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	naa80	ENSDARG00000068590
mus_musculus	Naa80	ENSMUSG00000079334
rattus_norvegicus	Naa80	ENSRNOG00000054063
drosophila_melanogaster	Naa80	FBGN0037747
caenorhabditis_elegans		WBGENE00016983

Protein

Protein identifiers

N-alpha-acetyltransferase 80 — Q93015 (reviewed: Q93015)

Alternative names: N-acetyltransferase 6, Protein fusion-2

All UniProt accessions (5): A0A1D5RMQ1, C9J451, C9JL88, Q6IAP1, Q93015

UniProt curated annotations — full annotation on UniProt →

Function. N-alpha-acetyltransferase that specifically mediates the acetylation of the acidic amino terminus of processed forms of beta- and gamma-actin (ACTB and ACTG, respectively). N-terminal acetylation of processed beta- and gamma-actin regulates actin filament depolymerization and elongation. In vivo, preferentially displays N-terminal acetyltransferase activity towards acid N-terminal sequences starting with Asp-Asp-Asp and Glu-Glu-Glu. In vitro, shows high activity towards Met-Asp-Glu-Leu and Met-Asp-Asp-Asp. May act as a tumor suppressor.

Subcellular location. Cytoplasm. Cytosol.

Tissue specificity. Strongly expressed in heart and skeletal muscle, followed by brain and pancreas, with weak expression in kidney, liver, and lung and no expression in placenta.

Disease relevance. Auroneurodental syndrome (ANDS) [MIM:620830] An autosomal recessive syndrome characterized by progressive high-frequency sensorineural hearing loss, craniofacial dysmorphism, developmental delay and mild proximal and axial muscle weakness. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the acetyltransferase family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q93015-1	1	yes
Q93015-2	2

RefSeq proteins (3): NP_001186945, NP_001186947, NP_036323 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000182	GNAT_dom	Domain
IPR016181	Acyl_CoA_acyltransferase	Homologous_superfamily
IPR039840	NAA80	Family

Pfam: PF00583

Enzyme classification (BRENDA):

• EC 2.3.1.B44 — (BRENDA: organisms, substrates, inhibitors, Km, kcat entries)

Catalyzed reactions (Rhea), 2 shown:

• N-terminal L-glutamyl-L-glutamyl-L-glutamyl-[protein] + acetyl-CoA = N-terminal N-acetyl-L-glutamyl-L-glutamyl-L-glutamyl-[protein] + CoA + H(+) (RHEA:57324)
• N-terminal L-aspartyl-L-aspartyl-L-aspartyl-[protein] + acetyl-CoA = N-terminal N-acetyl-L-aspartyl-L-aspartyl-L-aspartyl-[protein] + CoA + H(+) (RHEA:57328)

UniProt features (33 total): helix 8, strand 7, binding site 5, mutagenesis site 4, sequence variant 3, region of interest 2, chain 1, domain 1, splice variant 1, compositionally biased region 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
6NBE	X-RAY DIFFRACTION	2
6NBW	X-RAY DIFFRACTION	2.5
6NAS	X-RAY DIFFRACTION	2.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q93015-F1	75.62	0.50

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (5): 85; 90–93; 141–143; 149–154; 179

Mutagenesis-validated functional residues (4):

Position	Phenotype
83	in naa80mut; abolished acetyltransferase activity; when associated with q-148, d-151 and f-183.
148	in naa80mut; abolished acetyltransferase activity; when associated with f-83, d-151 and f-183.
151	in naa80mut; abolished acetyltransferase activity; when associated with f-83, q-148 and f-183.
183	in naa80mut; abolished acetyltransferase activity; when associated with f-83, q-148 and d-151.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 191 (showing top): GOBP_N_TERMINAL_PROTEIN_AMINO_ACID_ACETYLATION, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, GOBP_REGULATION_OF_ACTIN_FILAMENT_BASED_PROCESS, GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_SIZE, RICKMAN_METASTASIS_DN, GOBP_PROTEIN_MATURATION, JAZAG_TGFB1_SIGNALING_DN, GOBP_PROTEIN_ACETYLATION, GOBP_ACTIN_FILAMENT_ORGANIZATION, ARGGGTTAA_UNKNOWN, GOBP_PEPTIDYL_GLUTAMIC_ACID_MODIFICATION, LEE_CALORIE_RESTRICTION_NEOCORTEX_UP, GOBP_PROTEIN_ACYLATION

GO Biological Process (5): protein acetylation (GO:0006473), regulation of actin polymerization or depolymerization (GO:0008064), N-terminal peptidyl-aspartic acid acetylation (GO:0017190), N-terminal peptidyl-glutamic acid acetylation (GO:0018002), actin modification (GO:0030047)

GO Molecular Function (7): protein-N-terminal amino-acid acetyltransferase activity (GO:0004596), N-acetyltransferase activity (GO:0008080), acetyl-CoA binding (GO:1905502), protein binding (GO:0005515), transferase activity (GO:0016740), acyltransferase activity (GO:0016746), acyltransferase activity, transferring groups other than amino-acyl groups (GO:0016747)

GO Cellular Component (2): cytoplasm (GO:0005737), cytosol (GO:0005829)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
N-terminal protein amino acid acetylation	2
cellular anatomical structure	2
protein acylation	1
actin polymerization or depolymerization	1
regulation of actin filament length	1
regulation of actin filament organization	1
peptidyl-aspartic acid modification	1
peptidyl-glutamic acid modification	1
actin cytoskeleton organization	1
protein modification process	1
protein N-acetyltransferase activity	1
acetyltransferase activity	1
acyl-CoA binding	1
binding	1
catalytic activity	1
transferase activity	1
acyltransferase activity	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

246 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NAA80	GLYATL1	Q969I3	873
NAA80	NAA60	Q9H7X0	824
NAA80	NAA40	Q86UY6	794
NAA80	NAA10	P41227	774
NAA80	ESCO1	Q5FWF5	728
NAA80	ESCO2	Q56NI9	726
NAA80	NAA15	Q9BXJ9	690
NAA80	NAA20	P61599	644
NAA80	NAA30	Q147X3	598
NAA80	ATE1	O95260	585
NAA80	NAA50	Q9GZZ1	574
NAA80	HYPK	Q9NX55	489
NAA80	ACTG1	P02571	435
NAA80	FUS	P35637	418
NAA80	NAA35	Q5VZE5	396

IntAct

4 interactions, top by confidence:

A	B	Type	Score
PFN2	DIAPH1	psi-mi:“MI:0914”(association)	0.350
NAA80	PFN1	psi-mi:“MI:0914”(association)	0.350
EMG1	NAA80	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (16): NAT6 (Affinity Capture-MS), NAT6 (Two-hybrid), NAT6 (Two-hybrid), NAT6 (Two-hybrid), ACTA2 (Affinity Capture-MS), ACTBL2 (Affinity Capture-MS), NAT6 (Affinity Capture-MS), BACH2 (Affinity Capture-MS), PFN1 (Affinity Capture-MS), POTEKP (Affinity Capture-MS), ACTC1 (Affinity Capture-MS), ACTB (Affinity Capture-MS), NAT6 (Proximity Label-MS), NAT6 (Proximity Label-MS), NAT6 (Proximity Label-MS)

ESM2 similar proteins: A0JPN4, A2A8U2, A6QQD2, A7UA95, B0BM95, B0V3H4, E2RDP2, F1MLB4, J3QPC3, O15040, O94983, O95382, Q0QWG9, Q3U3N6, Q3U5Q7, Q3UYV8, Q400C9, Q400G9, Q5BKX5, Q5T7N3, Q60943, Q684M2, Q69ZT1, Q80Y50, Q86V42, Q86XL3, Q8BVF9, Q8C0R7, Q8CC12, Q8IWY9, Q8N9W5, Q8R2K4, Q91WA6, Q91XB0, Q924T7, Q93015, Q95K25, Q969H4, Q96EP0, Q96F46

Diamond homologs: Q59DX8, Q93015, Q9R123

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

2 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	1
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

658 predictions. Top by Δscore:

Variant	Effect	Δscore
3:50299211:A:AC	donor_gain	1.0000
3:50299212:C:CC	donor_gain	1.0000
3:50299207:A:AC	donor_gain	0.9900
3:50299208:C:CC	donor_gain	0.9900
3:50296892:CCCAG:C	donor_gain	0.9800
3:50299212:CATG:C	donor_gain	0.9800
3:50299212:CA:C	donor_gain	0.9700
3:50299061:T:TA	donor_gain	0.9600
3:50299204:GGTAC:G	donor_loss	0.9600
3:50299207:ACT:A	donor_loss	0.9600
3:50299208:CTG:C	donor_loss	0.9600
3:50299209:TGACA:T	donor_loss	0.9600
3:50299210:GA:G	donor_loss	0.9600
3:50299211:A:AT	donor_loss	0.9600
3:50299212:C:A	donor_loss	0.9600
3:50299205:GTACT:G	donor_loss	0.9500
3:50299206:TAC:T	donor_loss	0.9500
3:50299208:CTGA:C	donor_gain	0.9500
3:50299210:GACA:G	donor_loss	0.9500
3:50299211:A:C	donor_loss	0.9500
3:50299267:T:TA	donor_gain	0.9500
3:50299271:A:AC	donor_gain	0.9500
3:50299272:C:CC	donor_gain	0.9500
3:50296896:G:C	donor_gain	0.9400
3:50297673:C:CC	acceptor_gain	0.9400
3:50297671:TCCTG:T	acceptor_loss	0.9300
3:50297673:C:CA	acceptor_loss	0.9300
3:50297674:T:G	acceptor_loss	0.9300
3:50299225:G:A	donor_gain	0.9300
3:50297670:CTC:C	acceptor_gain	0.9200

AlphaMissense

1807 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:50296918:G:C	F182L	0.994
3:50296918:G:T	F182L	0.994
3:50296920:A:G	F182L	0.994
3:50297215:C:A	W83C	0.994
3:50297215:C:G	W83C	0.994
3:50297217:A:G	W83R	0.993
3:50297217:A:T	W83R	0.993
3:50296973:G:T	A164D	0.992
3:50297093:G:T	A124D	0.992
3:50296919:A:G	F182S	0.990
3:50296957:G:C	F169L	0.990
3:50296957:G:T	F169L	0.990
3:50296959:A:G	F169L	0.990
3:50297196:G:T	R90S	0.989
3:50297057:A:T	L136H	0.988
3:50296901:T:G	Y188S	0.987
3:50296943:A:G	L174P	0.987
3:50297094:C:G	A124P	0.987
3:50296902:A:C	Y188D	0.986
3:50297097:G:C	H123D	0.985
3:50296613:T:A	K284I	0.983
3:50296997:A:T	L156H	0.983
3:50297099:C:T	G122D	0.983
3:50297161:G:C	F101L	0.983
3:50297161:G:T	F101L	0.983
3:50297163:A:G	F101L	0.983
3:50297006:C:T	G153D	0.982
3:50297090:C:G	R125P	0.981
3:50297231:A:G	L78P	0.981
3:50296619:A:G	M282T	0.980

dbSNP variants (sampled 300 via entrez): RS1000264872 (3:50298681 C>A,T), RS1001823111 (3:50299658 C>T), RS1002895615 (3:50296517 G>C,T), RS1003761596 (3:50301184 G>A), RS1006278239 (3:50299444 C>A,G), RS1007115711 (3:50296278 C>A,T), RS1010410898 (3:50299075 C>G), RS1011385276 (3:50299993 A>G,T), RS1011415105 (3:50300347 A>T), RS1013329791 (3:50296779 C>A,T), RS1013583315 (3:50299520 C>T), RS1013610154 (3:50299650 G>C), RS1013916718 (3:50298002 T>C), RS1014362905 (3:50298340 T>C), RS1014933634 (3:50299447 C>G)

Disease associations

OMIM: gene MIM:607073 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
auroneurodental syndrome	Limited	Autosomal recessive

Mondo (1): auroneurodental syndrome (MONDO:0970998)

Orphanet (0):

HPO phenotypes

29 total (29 of 29 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000160	Narrow mouth
HP:0000219	Thin upper lip vermilion
HP:0000278	Retrognathia
HP:0000286	Epicanthus
HP:0000316	Hypertelorism
HP:0000369	Low-set ears
HP:0000407	Sensorineural hearing impairment
HP:0000411	Protruding ear
HP:0000508	Ptosis
HP:0000699	Diastema
HP:0001182	Tapered finger
HP:0001252	Hypotonia
HP:0001263	Global developmental delay
HP:0002066	Gait ataxia
HP:0002162	Low posterior hairline
HP:0002553	Highly arched eyebrow
HP:0003327	Axial muscle weakness
HP:0003593	Infantile onset
HP:0003701	Proximal muscle weakness
HP:0006342	Peg-shaped maxillary lateral incisors
HP:0006956	Lateral ventricle dilatation
HP:0010535	Sleep apnea
HP:0011968	Feeding difficulties
HP:0012378	Fatigue
HP:0012450	Chronic constipation
HP:0025372	Loud snoring
HP:0034295	Reduced cerebral white matter volume
HP:0100716	Self-injurious behavior

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST007559_24	Sleep duration (short sleep)	3.000000e-08

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases abundance, affects splicing, decreases expression	3
Particulate Matter	decreases expression, decreases reaction, increases abundance, increases expression	3
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Tobacco Smoke Pollution	decreases expression	2
GSK-J4	decreases expression	1
dicrotophos	increases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
sodium arsenate	decreases expression, increases abundance	1
beta-lapachone	decreases expression	1
arsenite	decreases expression, increases abundance	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
monomethylarsonic acid	decreases expression	1
pyrrolidine dithiocarbamic acid	decreases reaction, affects cotreatment, decreases expression	1
arsenic acid	decreases expression, increases abundance	1
cadmium acetate	increases expression	1
bathocuproine sulfonate	decreases expression, decreases reaction, affects cotreatment	1
monomethylarsonous acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases expression, decreases reaction	1
dorsomorphin	affects cotreatment, decreases expression	1
dimethylmonothioarsinic acid	decreases expression	1
jinfukang	increases expression, affects cotreatment	1
Bortezomib	decreases expression	1
Air Pollutants	increases abundance, decreases expression	1
Vehicle Emissions	decreases reaction, decreases expression	1
Cacodylic Acid	decreases expression	1
Cisplatin	affects cotreatment, increases expression	1
Diazinon	increases methylation	1
Doxorubicin	decreases expression	1
Gallic Acid	increases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SZ97	HAP1 NAT6 (-) 1	Cancer cell line	Male
CVCL_SZ98	HAP1 NAT6 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.